News & Updates
Filter by Specialty:
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
08 Nov 2021
byJairia Dela Cruz
A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
08 Nov 2021
Novel tenofovir formulation noninferior to disoproxil fumarate in chronic hepatitis B
08 Nov 2021
In the treatment of patients with chronic hepatitis B (CHB), the novel tenofovir amibufenamide (TMF) is as good as tenofovir disoproxil fumarate (TDF) in terms of efficacy but with the advantage of better bone and renal safety, according to the results of a noninferiority trial.
